Company news

Immatics N.V. news in 2023

Immatics N.V.'s news releases, calls and decks from 2023, newest first.

View company

Immatics Announces Third Quarter 2023 Financial Results and Business Update

November 13, 2023

Immatics Reports Interim Clinical Data from ACTengine® IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 Trial

November 7, 2023

Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA203 TCR-T Monotherapy

October 23, 2023

Immatics Announces Second Quarter 2023 Financial Results and Business Update

August 16, 2023

Immatics Initiates Phase 1/2 Clinical Trial to Evaluate PRAME TCR Bispecific IMA402 in Patients with Advanced Solid Tumors

August 9, 2023

Immatics Announces $35 Million Equity Investment from Bristol Myers Squibb

July 23, 2023

Immatics Announces First Quarter 2023 Financial Results and Business Update

May 15, 2023

Immatics Reports Interim Clinical Data from Ongoing Phase 1b Cohort A Monotherapy with ACTengine® IMA203 TCR-T Targeting PRAME

May 1, 2023

Immatics Announces First Bristol Myers Squibb Opt-in of TCR-T Candidate from Ongoing Multi-target Strategic Collaboration

April 30, 2023

Immatics Announces Full Year 2022 Financial Results and Corporate Update

March 20, 2023

Decks in 2023